NCT03945656View on ClinicalTrials.gov

A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

insulin icodec

Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks

DRUG

Insulin glargine

Participants will receive daily s.c. injections of insulin glargine U100 for 12 days

Trial Locations (1)

8010

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY